Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)
NCT ID: NCT01106742
Last Updated: 2011-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2009-03-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)
NCT01496053
The Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD Patients
NCT04329481
A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease
NCT04521205
Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis
NCT04029649
The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis
NCT03151850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AndoSan, UC
AndoSan as a supplement to 10 UC patents
AndoSan
AndoSan, 20mlx3, 12 days
AndoSan, CD
AndoSan as a supplement to 10 CD patients.
AndoSan
AndoSan, 20mlx3, 12 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AndoSan
AndoSan, 20mlx3, 12 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ullevaal University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ullevaal University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital, Department of Surgery
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AbM2009-IBD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.